Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

The Top 5 Biosimilar Articles for the Week of July 8

July 12th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of July 8, 2024.

Trastuzumab-dkst Matches Herceptin's Safety, Well-Being for HER2-Positive Breast Cancer

July 11th 2024

By Cameron Santoro

Article

Patients with HER2-positive breast cancer treated with the biosimilar trastuzumab-dkst experienced similar adverse events and well-being as those treated with the originator drug (Herceptin), according to a study using a smartphone app to track symptoms.

Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data

July 10th 2024

By Skylar Jeremias

Article

The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.

Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer

July 9th 2024

By Skylar Jeremias

Article

A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.

Biosimilars and Employers: Strategies for Success

July 8th 2024

By Kathy Oubre, MS

Article

The author, who is CEO of Pontchartrain Cancer Center, discusses how biosimilars can be part of a strategy for delivering high-quality care while achieving savings.

Biosimilars Oncology Roundup for June 2024—Podcast Edition

July 7th 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.

Samsung Bioepis’ Ustekinumab Biosimilar Demonstrates PK Equivalence in Healthy Adults

July 6th 2024

By Deana Ferreri, PhD

Article

A phase 1 study demonstrated pharmacokinetic (PK) bioequivalence of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the EU- and US-sourced reference products.

The Top 5 Biosimilar Articles for the Week of July 1

July 5th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of July 1, 2024.

Eye on Pharma: New Data, Clinical Developments, and Biosimilar Partnerships

July 4th 2024

By Skylar Jeremias

Article

As Celltrion publishes phase 3 data on its tocilizumab biosimilar, other companies finalize partnerships, and Formycon begins development for a pembrolizumab biosimilar.

Biosimilars Oncology Roundup: June 2024

July 2nd 2024

By Skylar Jeremias

Article

As the weather heats up for the US and Europe, so too did the biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.